Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + nivolumab + ipilimumab versus nivolumab + ipilimumab in previously untreated advanced or metastatic renal cell carcinoma
2018-004567-31Phase 3Unknown
- Sponsor
- Exelixis, Inc.
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Cabozantinib + nivolumab + ipilimumab with Nivolumab + ipilimumab (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2018-004567-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004567-31.